medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2015; 14 (4)


Inter and intrapatient evolution of hepatitis C virus

Di Lello FA, Culasso ACA, Campos RH

Idioma: Ingles.
Referencias bibliográficas: 77
Paginas: 442-449
Archivo PDF: 128.06 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non A non B viral hepatitis genome. Science 1989; 244: 359-62.

  2. Lavanchi D. The Global Burden of Hepatitis C. Liver Int 2009; 29: 74-81.

  3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  4. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 2014; 59: 318-27.

  5. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, et al. Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes. Hepatology 2005; 42: 962-73.

  6. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Review. Antivir Res 2003; 59: 1-11.

  7. Pujol FH, Devesa M. Genotypic variability of hepatitis viruses associated with chronic infection and the development of hepatocellular carcinoma. J Clin Gastroenterol 2005; 39: 611-8.

  8. Mira JA, Rivero A, de Los Santos-Gil I, López-Cortés LF, Girón-González JA, Márquez M, Merino D, et al. Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. AIDS 2012; 26: 1721-4.

  9. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S. Rapid evolution of RNA genomes. Science 1982; 215: 1577-85.

  10. Belshaw R, Sanjuán R, Pybus OG. Viral mutation and substitution: units and levels. Curr Opin Virol 2011; 1: 430-5.

  11. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842-8.

  12. Martell M, Esteban JI, Quer J, Genescà J, Weiner A, Esteban R, Guardia J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-9.

  13. Canobio S, Guilbert CM, Troesch M, Samson J, Lemay M, Pelletier VA, Bernard-Bonnin AC, et al. Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol 2004; 42: 4365-9.

  14. Veillon P, Payan C, Le Guillou-Guillemette H, Gaudy C, Lunel F. Mutation analysis of ISDR and V3 domains of Hepatitis C Virus NS5A region before interferon therapy with or without ribavirin. Pathologie Biologie 2004; 52: 505-10.

  15. Pellerin M, Lopez-Aguirre Y, Penin F, Dhumeaux D, Pawlotsky JM. Hepatitis C Virus Quasispecies Variability Modulates Nonstructural Protein 5A Transcriptional Activation, Pointing to Cellular Compartmentalization of Virus-Host Interactions. J Virol 2004; 78: 4617-27.

  16. Fan X, Mao Q, Zhou D, Lu Y, Xing J, Xu Y, Ray SC, et al. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 2009; 50: 1765-72.

  17. Ramachandran S, Campo DS, Dimitrova ZE, Xia GL, Purdy MA, Khudyakov YE. Temporal variations in the hepatitis C virus intrahost population during chronic infection. J Virol 2011; 85: 6369-80.

  18. Alfonso V, Flichman DM, Sookoian S, Mbayed VA, Campos RH. Evolutionary study of HVR1 of E2 in chronic hepatitis C virus infection. J Gen Virol 2004; 85: 39-46.

  19. Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, Rice CM, et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog 2008; 4: e1000143.

  20. Gray RR, Parker J, Lemey P, Salemi M, Katzourakis A, Pybus OG. The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol Biol 2011; 11: 131.

  21. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-44.

  22. Sheridan I, Pybus OG, Holmes EC, Klenerman P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 2004; 78: 3447-54.

  23. Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. J Gastroenterol Hepatol 2011; 26(Suppl. 1): 83-95.

  24. Alter JM. Epidemiology of hepatitis C virus infection. WJ Gastroenterol 2007; 13: 2436-41.

  25. Magiorkinis G, Sypsa V, Magiorkinis E, Paraskevis D, Katsoulidou A, Belshaw R, Fraser C, et al. Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol 2013; 9: e1002876.

  26. Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, Mumford JA, Holmes EC. Unifying the epidemiological and evolutionary dynamics of pathogens. Science 2004; 303: 327-32.

  27. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.

  28. Nattermann J, Timm J, Nischalke HD, Olbrich A, Michalk M, Tillmann HL, Berg T, et al. The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. J Hepatol 2011; 55: 1201-06.

  29. Ruiz-Extremera A, Muñoz-Gámez JA, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53: 1830-8.

  30. Wolinsky S, Wike C, Korber B, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, et al. Selective transmission of HIV- 1 variants from mothers to infants. Science 1992; 255: 1134-7.

  31. Derdeyn C, Decker J, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, et al. Envelope-constrained neutralization- sensitive HIV-1 after heterosexual transmission. Science 2004; 303: 2019-22.

  32. Edwards C, Holmes EC, Wilson D, Viscidi RP, Abrams EJ, Phillips RE, Drummond AJ. Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1. BMC Evol Biol 2006; 6: 28.

  33. Rambaut A, Posada D, Crandall K, Holmes E. The causes and consequences of HIV evolution. Nat Rev Genet 2004; 5: 52-61.

  34. Sawada L, Pinheiro AC, Locks D, Pimenta Ado S, Rezende PR, Crespo DM, Crescente JÂ, et al. Distribution of hepatitis C virus genotypes among different exposure categories in the State of Pará, Brazilian Amazon. Rev Soc Bras Med Trop 2011; 44: 8-12.

  35. Jamalidoust M, Namayandeh M, Asaei S, Aliabadi N, Ziyaeyan M. Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol 2014; 20: 5897-902.

  36. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-62.

  37. Morice Y, Roulot D, Grando V, Stirnemann J, Gault E, Jeantils V, Bentata M, et al. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol 2001; 82: 1001-12.

  38. Van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Rezza G, Broers B, et al. Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis. J Infect Dis 2004; 189: 292- 302.

  39. Cifuentes C, Mira JA, Vargas J, Neukam K, Escassi C, García-Rey S, Gilabert I, et al. Prevalence of hepatitis virus infection markers in HIV-infected patients in Southern Spain. Enferm Infecc Microbiol Clin 2012; 30: 452-7.

  40. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, et al. Pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 2004; 292: 2839-48.

  41. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, González-García J, Lazzarin A, Carosi G, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.

  42. Núñez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-82.

  43. Pineda JA, Mira JA, de los Santos-Gil I, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60: 1347-54.

  44. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004; 12: 96-102.

  45. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-45.

  46. Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, et al. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigenrestricted immune pressure. Hepatology 2009; 50: 1017-29.

  47. Posthouwer D, Fischer K, van Erpecum KJ, Mauser-Bunschoten EP. The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. Transfusion 2006; 46: 1360-6.

  48. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 8; 461: 798-801.

  49. Di Lello FA, Caruz A, Rallon NI, Rivero-Juarez A, Neukam K, Barreiro P, Camacho A, et al. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 2013; 32: 1427-35.

  50. Riva A, Laird M, Casrouge A, Ambrozaitis A, Williams R, Naoumov NV, Albert ML, et al. Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology 2014; 60: 487-96.

  51. Fitzmaurice K, Hurst J, Dring M, Rauch A, McLaren PJ, Günthard HF, Gardiner C, et al. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut 2014 [Epub ahead of print].

  52. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004; 40: 108-14.

  53. Kuniholm MH, Anastos K, Kovacs A, Gao X, Marti D, Sette A, Greenblatt RM, et al. Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus. Genes Immun 2013; 14: 330-5.

  54. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.

  55. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999; 73: 2938-46.

  56. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-78.

  57. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2: 30-2.

  58. Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, et al. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain From Wild Type Clone in Vivo. Hepatology 2011; 54: 781-8.

  59. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 2014; 105: 64-71.

  60. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282: 103-07.

  61. Domingo E, Sheldon J, Perales C. Viral quasispecies evolution. Microbiol Mol Biol Rev 2012; 76: 159-216.

  62. Smith JA, Aberle JH, Fleming VM, Ferenci P, Thomson EC, Karayiannis P, McLean AR, et al. Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis 2010; 202: 1770-9.

  63. Alfonso V, Mbayed VA, Sookoian S, Campos RH. Intra-host evolutionary dynamics of hepatitis C virus E2 in treated patients. J Gen Virol 2005; 86: 2781-6.

  64. Li H, McMahon BJ, McArdle S, Bruden D, Sullivan DG, Shelton D, Deubner H, et al. Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology 2008; 375: 580-91.

  65. Gray RR, Salemi M, Klenerman P, Pybus OG. A new evolutionary model for hepatitis C virus chronic infection. PLoS Pathog 2012; 8: e1002656.

  66. Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF, Restivo L, Zappia V, et al. Microsomal triglyceride transfer protein (MTP)-493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat 2008; 15: 740-6.

  67. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72.

  68. Jacobson I, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, Moroz L, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment- naive patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58(Suppl. 1): S574.

  69. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005; 79: 3071-83.

  70. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis 2006; 193: 931-40.

  71. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23-38.

  72. Verbinnen T, Jacobs T, Vijgen L, Ceulemans H, Neyts J, Fanning G, Lenz O. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays. J Antimicrob Chemother 2012; 67: 2327-37.

  73. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87: 1544-53.

  74. Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, Kwong AD, Garg V, et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease- inhibitor resistant variants. PLoS Comput Biol 2010; 6: e1000745.

  75. Middleton TY, He T, Pilot-Matias R, Tripathi BH, Lim A, Roth CM, Chen G, et al. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J Virol Methods 2007; 145: 137-45.

  76. Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, et al. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res 2009; 81: 166-73.

  77. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646-54.




2020     |     www.medigraphic.com